TABLE 6.

Evaluation of three 1% formulations of dendrimer SPL7013 against genital herpes in micee

TreatmentConcn (mg/ml)Fraction (%) of animals protected against:
DiseaseInfection
SPL7013 formulation 1V1011/16 (69)a,c11/16 (69)a,d
Placebo 1V3/16 (19)1/16 (6)
SPL7013 formulation 2V1012/16 (75)a12/16 (75)a,c
Placebo 2V7/16 (44)b4/16 (25)
SPL7013 formulation 3V1013/15 (87)a,c12/15 (80)a,c
Placebo 3V6/16 (38)b4/16 (25)
PBS1/16 (6)1/16 (6)
  • a P < 0.001 versus PBS.

  • b P < 0.05 versus PBS.

  • c P < 0.05 versus placebo.

  • d P < 0.001 versus placebo.

  • e Mice were treated 5 min prior to challenge.